This activity is supported by an unrestricted educational grant from Astellas Pharma US, Boehringer Ingelheim Pharmaceuticals, Inc., Genentech, Inc., Pfizer
Navigating the Landscape of Molecular Testing and Treatments With Targeted Therapies for Patients With Non-Small Cell Lung Cancer
Sukhmani K. Padda, MD
Stanford Cancer Institute
R. Donald Harvey, PharmD, FCCP, BCOP
Winship Cancer Institute of Emory University
Keeping current with emerging targeted therapies for NSCLC can be daunting yet exciting. There are multiple options for first, second and even third line treatment, which can effectively delay progression or improve overall survival. This activity provides the AP with a valuable overview and update on NSCLC targeted therapies, molecular testing and recommendations for optimizing patient outcomes with newer emerging treatment options.
These CME/CE/CPE accredited activities are jointly provided by